PubMed
Kisspeptin signaling in reproductive biology
Pinilla et al., 2012
Hormonal & EndocrineResearch OnlyB
Kisspeptin
Kisspeptin-10
Neuropeptide signaling regulator of the GnRH axis, studied for reproductive endocrinology.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 6
- Research grade
- B
- Experience
- 15
- Activity
- 49
Overall check-ins
Trackers & reports
Overview
About Kisspeptin
Neuropeptide signaling regulator of the GnRH axis, studied for reproductive endocrinology.
- Category
- Hormonal & Endocrine
- Regulatory status
- Research Only
- Also known as
- Kisspeptin-10
- Self-reports
- 29
Community
What 29 users report
29 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 4% · Unfavorable overall 93%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Libido
150
Self-reported dose per injection
Median bucket: 200–400 mcg · Most common: 200–400 mcg
Reports span 100–1000 mcg
100–200
46
200–400
102
400–600
1
600–1000
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 78% said they felt similar to their last entry, 22% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 160 days · Based on 23 repeat reporters
Research
Cited research (5)
Source
PubMed
Kisspeptin in the control of reproduction
Skorupskaite et al., 2018
ClinicalTrials.gov
Kisspeptin studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Pubertal development and regulation
Abreu et al., 2016
PubMed
Kisspeptin and fertility
Hameed et al., 2011
Tools
Explore more
Explore
More ways to learn about Kisspeptin from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about Kisspeptin?
This page summarizes 29 anonymized self-reports from PeptIQ users who track Kisspeptin, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Kisspeptin?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Kisspeptin?
5 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Kisspeptin safe to use?
This wiki does not assess safety or recommend use. Kisspeptin is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Kisspeptin?
Research, primarily in animal models, suggests Kisspeptin may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of Kisspeptin?
Kisspeptin is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Kisspeptin as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of Kisspeptin?
The safety and effectiveness of Kisspeptin have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on Kisspeptin?
While there are over 200 published studies on Kisspeptin, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source